Quotes 5-day view Delayed Nasdaq
02/19/2021
02/22/2021
02/23/2021
02/24/2021
02/25/2021
Date
470.37(c)
460.58(c)
468.03(c)
458.6(c)
453.19 Last
1 129 917
1 345 550
1 705 566
1 103 374
1 125 287 Volume
-1.40% -2.08% +1.62% -2.01% -1.18% Change
Sales 2021
11 907 M - -
Net income 2021
4 788 M - -
Net cash position 2021
9 807 M - -
P/E ratio 2021
10,7x
Yield 2021
-
Sales 2022
11 297 M - -
Net income 2022
4 174 M - -
Net cash position 2022
13 742 M - -
P/E ratio 2022
12,2x
Yield 2022
-
Capitalization
47 761 M 47 761 M -
EV / Sales 2021
3,19x
EV / Sales 2022
3,01x
Nbr of Employees
9 123
Free-Float
82,7%
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:
- sales of products (65.5%);
- supply of collaborative services (27.9%): working with Sanofi (50% of sales) and Bayer (50%);
- sales of technology licenses (6.6%). The group also provides subcontracting research...
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
All news about REGENERON PHARMACEUTICALS
News in other languages on REGENERON PHARMACEUTICALS
Analyst Recommendations on REGENERON PHARMACEUTICALS
U.S. hospitals to restrict Lilly COVID-19 antibody treatment due to limited supply
Chart REGENERON PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends REGENERON PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Bearish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
27
Average target price
639,60 $
Last Close Price
458,60 $
Spread / Highest target
73,4%
Spread / Average Target
39,5%
Spread / Lowest Target
9,03%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
